Hansa Biopharma at a glance

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

The Company’s lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications.

Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020.

Hansa’s research and development program is advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and has operations in both Europe and the U.S.


Our Equity Story

Imlifidase works
Targeting rare diseases with a high unmet medical need
Addresses a clear unmet need
Preparing for commercialization
Well positioned for commercial success
Evolution into a fully integrated biopharmaceutical company
Rich pipeline
Leveraging our proprietary antibody cleaving enzyme technology

Learn More



Latest Financial Results

View All Results
View all news

Latest News

View all events

Upcomming Events

Milestones and near-term news flow

Near Term News Near Term News



For any investor related inquiries, please contact IR@hansabiopharma.com